Source: FinanzNachrichten

Tiziana Life Sciences: Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the 37th Annual Roth Conference

NEW YORK, March 17, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully...

Read full article »
Annual Revenue
$5.0-25M
Employees
1-25
Ivor Elrifi's photo - CEO of Tiziana Life Sciences

CEO

Ivor Elrifi

CEO Approval Rating

82/100

Read more